General form of registration statement for all companies including face-amount certificate companies

Consolidated Statements of Operations

v3.23.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:    
Research and development expenses $ 8,933,314 $ 3,496,796
General and administrative expenses 6,143,527 4,289,831
Ratchet share expense 1,099,360  
Total operating expenses 16,176,201 7,786,627
Loss from operations (16,176,201) (7,786,627)
Other income (expense):    
Interest expense (6,967) (827,539)
Interest income 1,870 2,012
Australian research and development incentives 313,625 43,666
Paycheck protection program loan forgiveness   62,500
Change in fair value of embedded features (203,000) (203,000)
Change in fair value of warrant liability 98,394 (1,546,280)
Loss on extinguishment of convertible notes and convertible notes, related parties   (2,322,943)
Other income (expense), net 406,922 (4,791,584)
Net loss (15,769,279) (12,578,211)
Net loss attributable to noncontrolling interests   (74,331)
Deemed dividend on warrant modification (450,578)  
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ (16,219,857) $ (12,503,880)
Net loss per share    
Basic and diluted $ (1.75) $ (2.37)
Weighted average common shares outstanding basic and diluted 9,276,761 5,278,435